Attached files

file filename
S-1/A - AMENDMENT NO. 1 TO FORM S-1 - XpresSpa Group, Inc.ds1a.htm
EX-1.1 - FORM OF UNDERWRITING AGREEMENT - XpresSpa Group, Inc.dex11.htm
EX-4.6 - FORM OF UNDERWRITER UNIT PURCHASE OPTION - XpresSpa Group, Inc.dex46.htm
EX-4.5 - FORM OF MANAGEMENT OPTION AGREEMENT - XpresSpa Group, Inc.dex45.htm
EX-5.1 - OPINION OF ELLENOFF GROSSMAN & SCHOLE LLP - XpresSpa Group, Inc.dex51.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - XpresSpa Group, Inc.dex231.htm
EX-10.23 - MARKETING AGREEMENT - XpresSpa Group, Inc.dex1023.htm
EX-10.21 - FORM OF EXCHANGE AGREEMENT - SERIES B CONVERTIBLE PREFERRED STOCK - XpresSpa Group, Inc.dex1021.htm
EX-10.19 - FORM OF STOCK PURCHASE AGREEMENT - XpresSpa Group, Inc.dex1019.htm
EX-10.22 - EMPLOYMENT AGREEMENT - ANDREW PERLMAN - XpresSpa Group, Inc.dex1022.htm
EX-4.4 - FORM OF WARRANT AGREEMENT - XpresSpa Group, Inc.dex44.htm

Exhibit 10.20

EXCHANGE OFFER AGREEMENT

This EXCHANGE OFFER AGREEMENT, dated as of December 29, 2009 (the “Agreement”) is made and entered into by and among Vringo, Inc., a Delaware corporation (the “Company”), Vringo (Israel) Ltd., a corporation organized under the laws of Israel and a wholly-owned subsidiary of the Company (the “Subsidiary”), and each of the undersigned holders (each a “Series A Holder”, and collectively, the “Series A Holders”) of the Series A Convertible Preferred Stock of the Company, par value $0.01 per share (the “Series A Shares”).

RECITALS

WHEREAS, the Series A Holders currently hold all of the 2,353,887 issued and outstanding shares of the Series A Shares;

WHEREAS, the Company, the Subsidiary, the Series A Holders and the holders of the Series B Convertible Preferred Stock of the Company, par value $0.01 per share (the “Series B Holders”) are parties to that certain Investor Rights Agreement dated July 30, 2007 (the “Investor Rights Agreement”);

WHEREAS, the Company, the Series A Holders, the Series B Holders and the holders of the common stock of the Company, par value $0.01 per share (the “Common Stock”) have entered into that certain Right of First Refusal, Co-Sale and Voting Agreement dated July 30, 2007 (the “ROFR Agreement”, and collectively with the Investor Rights Agreement, the “Series A Agreements”);

WHEREAS, the Company has engaged Maxim Group LLC (“Maxim”) to act as the Company’s placement agent in connection with a private placement of convertible notes and warrants of the Company in a minimum amount of $2,500,000 and a maximum amount of $3,000,000 (the “Offering”);

WHEREAS, the Company anticipates that subsequent to the consummation of the Offering, it will conduct an underwritten initial public offering of newly issued units, each comprised of one share of Common Stock and two warrants, with each warrant representing a right to purchase one share of Common Stock at an exercise price equal to 110% of the IPO Offering Price (as defined below) (“Units”), at an offering price that is anticipated to be $5.00 per Unit (the actual offering price, the “IPO Offering Price”), following the effective date of, and pursuant to, a registration statement that will be filed with the Securities and Exchange Commission (the “SEC”) with respect to the initial public offering of the Units (the “Registration Statement”) and that provides for the listing of such Units on the Nasdaq Capital Market, the NYSE Amex, the OTC Bulletin Board or other similarly recognized national trading platform (the “IPO”);

WHEREAS, immediately prior to the IPO, the Company will execute a 1 for 6 reverse split of all shares of Common Stock in the event the IPO Offering Price is greater than or equal to $4.00 and a 1 for 6.4 reverse split in the event the IPO Offering Price is less than $4.00 (the “Reverse Split”);


WHEREAS, the Company and the Series A Holders desire to conduct a share exchange pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended (the “Act”), pursuant to which the Series A Holders will exchange all of their currently issued and outstanding Series A Shares for shares of Common Stock; and

WHEREAS, the Company, the Subsidiary and the Series A Holders executing this Agreement, constituting at least 75% of the outstanding Series A Shares, desire to terminate the Series A Agreements and accept the consideration set forth herein in lieu of the rights set forth in the Series A Agreements.

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises, representations and covenants and agreements herein contained, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

  1. Effective Date. The terms and conditions of this Agreement shall be deemed effective as of the date of the consummation of the IPO (the “Effective Date”). This Agreement shall automatically terminate and become null and void upon the earliest of (i) December 31, 2009 if the Company fails to close the Offering, as contemplated by the term sheet attached hereto as Exhibit A, on or before such date, (ii) January 31, 2010 if the Registration Statement is not filed with the SEC on or before such date, (iii) August 10, 2010 if the SEC has not declared the Registration Statement effective on or before such date and (iv) the date on which the Company files with the SEC an application to withdraw the Registration Statement.

 

  2. Exchange of Shares. On the Effective Date and subject to the Reverse Split thereafter and the terms and conditions of this Agreement, the Series A Holders hereby covenant and agree to exchange and transfer the 2,353,887 Series A Shares they hold to the Company and the Company hereby covenants and agrees to issue to the Series A Holders shares of Common Stock (“New Shares”) in the following amounts and as set forth opposite each Series A Holder’s name in Exhibit B:

 

  a. If the IPO Offering Price is greater than $4.49, in a ratio of 1.15 New Shares for each Series A Share so exchanged for an aggregate amount of 2,706,970 New Shares;
  b. If the IPO Offering Price is equal to or greater than $4.00 and equal to or less than $4.49, in a ratio of 1.016 New Shares for each Series A Share so exchanged for an aggregate amount of 2,391,549 New Shares; and
  c. If the IPO Offering Price is less than $4.00, in a ratio of 1.066 New Shares for each Series A Share so exchanged for an aggregate amount of 2,509,244 New Shares.

Prior to the consummation of the IPO, the Company shall not effect any stock dividend, stock split, stock distribution or combination, subdivision, reclassification or other corporate actions having a similar effect with respect to the Series A Shares or the Common Stock, other than the Reverse Split, without the consent of a Series A Holders holding a majority of the Series A Shares.


The Company represents and warrants that, as of the Effective Date, the New Shares will be duly authorized and, upon issuance, exchange and transfer as contemplated by this Agreement, the New Shares will be validly issued, fully paid and non-assessable shares of the Company.

 

  3. Lockup of Securities. The Series A Holders hereby covenant and agree to comply with the lock-up provisions set forth in Exhibit C.

 

  4. Termination of Series A Agreements. On the Effective Date, the Series A Agreements shall be terminated and cancelled and be of no further force or effect.

 

  5. Waiver. On the Effective Date, each party hereby waives, releases, acquits, and forever discharges the other party and its respective agents, representatives, officers, directors, and employees from any and all claims, causes of action, liability or damages of any kind, whether past or present, known or unknown, real or imagined, asserted or unasserted, foreseen or unforeseen that each party could have asserted in connection with the Series A Agreements. Each party represents and warrants that it has not and will not assign, transfer, or dispose of, in any manner, any interest (either in whole or in part) in any claims, causes of action, liability or damages that are the subject of the foregoing sentence.

 

  6. Condition Precedent. It shall be a condition precedent to the obligations of the parties to consummate this Agreement that the Company enter into an agreement with the Series B Holders that is substantially similar to this Agreement and that the Company deliver a copy of such executed agreement to the Series B Holders.

 

  7. Entire Agreement. This Agreement sets forth the entire agreement and understanding between the parties as to the subject matter thereof and merges and supersedes all prior discussions, agreements and understandings of any and every nature among them.

 

  8. Counterparts; Governing Law. This Agreement may be executed in one or more counterparts, which taken together shall constitute one and the same instrument. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

[SIGNATURE PAGES FOLLOW]


IN WITNESS WHEREOF, the parties have caused this Agreement to be executed and delivered by their duly authorized representatives as of the date first written above.

 

VRINGO, INC.
By:    

Name:

Title:

VRINGO (ISRAEL) LTD.
By:    

Name:

Title:


Series A Holder
  
Name: